Drug Trial Radar · NCT07276373
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jan 16, 2026
Primary completion
Sep 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Conditions
- Neoplasms
Interventions
Nenocorilant 200 mgDrug
Nenocorilant 200 mg will be supplied as 50 and/or 100 mg tablets.
Nenocorilant 300 mgDrug
Nenocorilant 300 mg will be supplied as 50 and/or 100 mg tablets.
Nenocorilant 400 mgDrug
Nenocorilant 400 mg will be supplied as 50 and/or 100 mg tablets.
NivolumabDrug
Nivolumab 240 mg and 480 mg will be supplied as single-dose 120 mg/12 mL (10 mg/mL) vials.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With 1 or More Adverse EventTime frame: From first dose of study treatment up to 28 days after final dose, assessed up to 9 months
- Number of Patients With 1 or More Serious Adverse EventsTime frame: From first dose of study treatment up to 28 days after final dose, assessed up to 9 months
- Number of Patients With 1 or More Adverse Events Leading to Study Drug DiscontinuationTime frame: From first dose of study treatment up to final dose, assessed up to 9 months
- Percent of Patients who Experience Dose Limiting Toxicity (DLT)Time frame: Up to 28 days after initiation of Cycle 1 (each cycle consists of 28 days)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Site 03
Los Angeles, California · Recruiting
Site 05
Chicago, Illinois · Recruiting
Site 04
Grand Rapids, Michigan · Recruiting
Site 01
San Antonio, Texas · Recruiting
Site 02
West Valley City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.